Status:

NOT_YET_RECRUITING

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

Lead Sponsor:

Akeso

Conditions:

HCC

Hepatocellular Carcinoma

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocell...

Eligibility Criteria

Inclusion

  • Signed the Informed Consent Form (ICF) voluntarily.
  • Age ≥18 years at time of signing ICF.
  • Histologic or cytologic confirmation of HCC, or clinical diagnosis of HCC as per AASLD criteria.
  • BCLC stage B or C, and not suitable for curative surgical or local therapy.
  • Participants have progressed on the prior first-line systemic treatment with atezolizumab plus bevacizumab combination treatment.
  • At least one measurable lesion according to RECIST v1.1.
  • Child-Pugh Class A .
  • ECOG performance status of 0 or 1.
  • With a life expectancy of ≥3 months.
  • Adequate organ and hematologic function.

Exclusion

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
  • Tumor thrombus invasion of superior mesenteric vein.
  • Has a known history of, or any evidence of CNS metastases.
  • Has received anti-cancer therapy for HCC within 3 weeks prior to the first dose of study treatment.
  • Has received systemic anti-cancer therapy other than atezolizumab and bevacizumab.
  • Has participated in another clinical study within 4 weeks prior to the first dose.
  • History of liver transplantation.
  • History of hepatic encephalopathy.
  • Clinically symptomatic or recurrently drained pleural effusion, pericardial effusion, or ascites.
  • History of bleeding event due to esophageal and/or gastric varices within 6 months prior to the first dose of study treatment.

Key Trial Info

Start Date :

June 25 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06984718

Start Date

June 25 2025

End Date

June 30 2027

Last Update

May 22 2025

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.